Messenger RNA medicines company Arcturus Therapeutics Holdings Inc (Nasdaq:ARCT) announced on Thursday that it has entered into a strategic collaboration with Thermo Fisher Scientific Inc (NYSE:TMO) to support Phase 3 development and potential commercialisation of ARCT-032, an investigational mRNA therapy for cystic fibrosis.

The agreement focuses on advancing clinical and manufacturing capabilities for the programme.

The collaboration will leverage Thermo Fisher's Accelerator Drug Development platform, integrating manufacturing, clinical research, and commercial readiness services. Thermo Fisher will support Phase 3 manufacturing and clinical research activities through its PPD clinical research business, subject to positive Phase 2 results.

If ARCT-032 receives regulatory approval, Thermo Fisher will obtain exclusive commercial manufacturing rights under a separate agreement. The arrangement is designed to support development continuity from late-stage clinical trials through potential market launch.